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Introduction
Hepatic drug metabolism by cytochrome P450 type 3A
(CYP3A) is impaired in patients with acute kidney
injury (AKI) [1]. The mechanisms underlying this are
unclear. CYP2D6 is another clinically important hepa-
tic CYP subtype, responsible for approximately 25%
drug metabolism. Common phenotypic variation
exists, the clinical relevance of which has not been
previously demonstrated in the critically ill. Tramadol
is a drug probe principally of CYP2D6 metabolism.
M1 is formed by CYP2D6, and M2 by CYP3A4. In a
pilot study, we showed that single time point determi-
nation of tramadol concentration 4 hours after IV tra-
madol bolus accurately predicts integral tramadol
exposure and hence tramadol metabolism in critically
ill adults [2].
Objectives
We aimed to investigate if an association exists between
CYP2D6 drug metabolism and AKI in critically ill
adults. We also investigated the importance of geneti-
cally predicted CYP2D6 phenotype (poor, intermediate
and extensive metabolisers) for drug metabolism in criti-
cally ill adults.
Methods
As part of a study of drug metabolism, 72 consented criti-
cally ill adults received IV 10mg tramadol bolus at t= 0.
Serum was collected prior to injection and at 4 hours for
determination of serum tramadol and tramadol metabolite
concentration by HPLC/MS/MS. Blood was analysed for
CYP2D6 genotype. Data were collected to determine AKI
severity by KDIGO classification. Glomerular filtration
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Table 1 Patient Characteristics median [range]
All Patients KDIGO 0 KDIGO 1 KDIGO 2 KDIGO 3
Patient No. 72 14 14 16 28
Patient Age 72 [19-88] 75 [22-88] 72.5 [50-82] 72.5 [59-83] 72 [19-88]
Baseline Serum Creatinine (mmol/L) 86 [34-259] 84 [69-112] 94 [58-162] 90 [61-259] 75 [34-221]
Illness Severity Score SOFA/APACHE II 8 [0-16]/ 20 [5-34] 7 [0-11]/ 18 [5-31] 8 [3-16]/ 18 [9-24] 7.5 [4-14]/ 17.5 [13-25] 10 [3-15]/ 20 [13-34]
Reason for admission Medical/Elective
surgery/Emergency surgery
46/11/14 7/2/2 10/2/2 8/6/2 21/1/6
BMI 26.42 [17.3-40.4] 25.1 [19.3-39.8] 25.3 [17.3-37.1] 26.4 [20.1-39.3] 28.5 [17.8-40.4]
CYP2D6 Phenotype PM/IM/IMEM/EM/
UEM/Unknown
7/24/2/36/1/2 1/6/0/7/0/0 2/3/0/9/0/0 1/5/1/8/1/0 3/10/1/12/0/2
Serum Creatinine at t = 0 (mmol/L) 178 [62-642] 97 [62-126] 156[66-223] 187 [81-280] 281 [74-642]
Time with AKI (h) [KDIGO 0 excluded] 35.5 [6-192] NA 24 [6-72] 37.5 [6-144] 36 [16-192]
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rate was assessed by simultaneous 4 hour urinary creati-
nine clearance (4CrCl) measurements. The clinical study
was approved by the local ethics committee.
Results
Baseline characteristics did not vary between groups.
The median serum tramadol concentration at 4 hours
for KDIGO 0-3 were 31.4, 29.6, 27.3 and 33.4 respec-
tively. No significant difference in tramadol concentra-
tion by KDIGO class (Kruskal Wallis, p = 0.78), AKI
duration, serum creatinine or urea or 4CrCl was found.
Tramadol concentration and those of its metabolites
varied significantly with CYP2D6 phenotype (Kruskal
Wallis, p = 0.005 for Tramadol, p = 0.0002 for M1, p =
0.0008 for M2).
When CYP2D6 phenotypes (IM, EM) were considered
individually, no effect of AKI was seen on tramadol con-
centration (p = 0.83 and 0.50, Kruskal-Wallis).
Conclusions
In contrast to CYP3A4, CYP2D6 metabolism does not
appear to be affected by AKI severity or duration. Tra-
madol metabolism is strongly influenced by genetically
predicted CYP2D6 phenotype in the critically ill and is
likely to reflect wide variation in CYP2D6 substrate
metabolism in general.
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